On Monday, Novo Nordisk ADR (NYSE: NVO) opened lower -3.52% from the last session, before settling in for the closing price of $79.83. Price fluctuations for NVO have ranged from $57.00 to $148.15 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 18.15% annually for the last half of the decade. Company’s average yearly earnings per share was noted 26.29% at the time writing. With a float of $3.37 billion, this company’s outstanding shares have now reached $3.37 billion.
In an organization with 76302 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 84.33%, operating margin of 44.53%, and the pretax margin is 43.65%.
Novo Nordisk ADR (NVO) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Novo Nordisk ADR is 0.00%, while institutional ownership is 9.71%. The most recent insider transaction that took place on May 30 ’25, was worth 1,972,859.
Novo Nordisk ADR (NVO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 26.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.78% during the next five years compared to 21.74% growth over the previous five years of trading.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
Check out the current performance indicators for Novo Nordisk ADR (NVO). In the past quarter, the stock posted a quick ratio of 0.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.95. Likewise, its price to free cash flow for the trailing twelve months is 18.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.37, a number that is poised to hit 0.90 in the next quarter and is forecasted to reach 4.72 in one year’s time.
Technical Analysis of Novo Nordisk ADR (NVO)
Let’s dig in a bit further. During the last 5-days, its volume was 9.7 million. That was better than the volume of 9.48 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 79.07%. Additionally, its Average True Range was 2.53.
During the past 100 days, Novo Nordisk ADR’s (NVO) raw stochastic average was set at 54.40%, which indicates a significant decrease from 66.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.35% in the past 14 days, which was lower than the 48.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $67.57, while its 200-day Moving Average is $92.38. However, in the short run, Novo Nordisk ADR’s stock first resistance to watch stands at $78.06. Second resistance stands at $79.10. The third major resistance level sits at $79.82. If the price goes on to break the first support level at $76.30, it is likely to go to the next support level at $75.58. The third support level lies at $74.54 if the price breaches the second support level.
Novo Nordisk ADR (NYSE: NVO) Key Stats
There are currently 4,487,530K shares outstanding in the company with a market cap of 259.26 billion. Presently, the company’s annual sales total 42,108 M according to its annual income of 14,643 M. Last quarter, the company’s sales amounted to 11,018 M and its income totaled 4,097 M.
